EP
AZN icon

Eversept Partners’s AstraZeneca AZN Stock Holding History

Eversept Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150,150
Closed -$19.8M – 74
2022
Q2 		$19.8M Sell
150,150
-136,000
-48% -$17.8M 1.41% 18
2022
Q1 		$38M Hold
286,150
– – 2.92% 12
2021
Q4 		$33.3M Buy
286,150
+156,000
+120% +$18.4M 2.13% 15
2021
Q3 		$15.6M Buy
+130,150
New +$15.2M 1.08% 26

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Eversept Partners's AZN Position: Q1 2025 in Review

Eversept Partners sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 51,331 shares — an estimated $6.73M sold.

Eversept Partners first reported a position in AZN in Q4 2019 and held it in 12 quarters. The position peaked at $67.4M in Q2 2022. 1,249 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

  • Eversept Partners reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
  • Eversept Partners sold 51,331 AstraZeneca shares in Q1 2025, an estimated $6.73M.
  • Eversept Partners first reported a position in AstraZeneca in Q4 2019 and held it in 12 quarters.
  • Eversept Partners's AstraZeneca position peaked at $67.4M in Q2 2022.
  • 1,249 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Eversept Partners's 13F filing for Q1 2025, filed 15 May 2025.